Across all tumours, multimodal analyses of paired patient biopsies pre- and post-treatment demonstrated that combined MTL-CEBPA and pembrolizumab treatment resulted in significantly increased intratumoural infiltration of proliferating cytotoxic CD8 + T cells and inflammatory HLA-DR + myeloid populations, as well as positive enrichment of associated immune activation gene pathways and reduction in genes associated with immunosuppression. This evidence concerns the gene CEBPA and neoplasm.